1. Generics Bulletin

Celltrion And Rani Partner For Oral Adalimumab

Deal For Humira Rival Builds On Collaboration For Oral Version Of Ustekinumab

 
• By Dave Wallace

Celltrion has doubled down on its alliance with Rani Therapeutics for oral pill versions of biosimilars by adding adalimumab to an existing collaboration covering ustekinumab.

Purple pills, capsules
Celltrion and Rani are developing an oral Humira rival • Source: Shutterstock

Celltrion and Rani Therapeutics are to collaborate to develop an orally-delivered version of biosimilar Humira (adalimumab), building on an existing partnership that covers a pill formulation of Celltrion’s rival to Stelara (ustekinumab).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin